Catatonia, neuroleptics and brain damage - A case report

Journal of Psychopharmacology

Volumn 23, Issue 2, 2009, Pages 223-226

  Chandran, M ^a   El Shazly, M ^b  

^a QUEEN ELIZABETH PSYCHIATRIC HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Catatonia; Cortical atrophy; Neuroleptic malignant syndrome; Temporal lobe epilepsy

Indexed keywords

AMISULPRIDE; LAMOTRIGINE; OLANZAPINE; VENLAFAXINE; DRUG DERIVATIVE; NEUROLEPTIC AGENT; SULPIRIDE; SULTOPRIDE;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN DAMAGE; CASE REPORT; CATATONIA; CLINICAL FEATURE; ELECTROCONVULSIVE THERAPY; FEMALE; HUMAN; NEUROLEPTIC MALIGNANT SYNDROME; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SIDE EFFECT; SKIN ALLERGY; TACHYCARDIA; TEMPORAL LOBE EPILEPSY; ATROPHY; CHEMICALLY INDUCED DISORDER; FRONTAL LOBE; MIDDLE AGED; PARIETAL LOBE; PATHOLOGY; PSYCHOSIS;

ANTIPSYCHOTIC AGENTS; ATROPHY; CATATONIA; EPILEPSY, TEMPORAL LOBE; FEMALE; FRONTAL LOBE; HUMANS; MIDDLE AGED; NEUROLEPTIC MALIGNANT SYNDROME; PARIETAL LOBE; PSYCHOTIC DISORDERS; SULPIRIDE;

EID: 67651159325     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108091257     Document Type: Article

References (24)

1. Adityanjee Sajatovic, M, Munshi, KR (2005) Neuropsychiatric sequelae of neuroleptic malignant syndrome. Clin Neuropharmacol 28: 197 - 204.
2. Baca L, Martinelli L, (1990) Neuroleptic malignant syndrome: a unique association with a tricyclic antidepressant. Neurology 40: 1797 - 1798.
3. Benjelloun G, Jehel L, Abgrall G, Pelissolo A, Allilaire J, (2005) Acute catatonic syndrome after neuroleptic malignant syndrome. Encephale 31: 705 - 709.
4. Berardi D, Amore M, Keck PE, Troia M, Dell'Atti M, (1998) Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study. Biol Psychiatry 44: 748 - 754.
5. Caroff SN, Mann SC, Campbell EC, (2000a) Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatric Ann 30: 314 - 321.
6. Caroff SN, Mann SC, Keck PE, Francis A, (2000b) Residual catatonic state following neuroleptic malignant syndrome. J Clin Psychopharmacol 20: 257 - 259.
7. Farver DK, (2003) Neuroleptic malignant syndrome induced by atypical antipsychotics. Expert Opin Drug Saf 2: 21 - 35.
8. Fink M, (2001) Treating neuroleptic malignant syndrome as catatonia. J Clin Psychopharmacol 21: 121.
9. Fink M, Taylor MA, (2001) The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci 251 (Suppl. 1). 18 - 13.
10. Gerlach J, Peacock L, (1995) New antipsychotics: the present status. Int Clin Psychopharmacol 10 (Suppl. 3). 39 - 48.
11. Gill J, Singh H, Nugent K, (2003) Acute lithium intoxication and neuroleptic malignant syndrome. Pharmacotherapy 23: 811 - 815.
12. Hasan S, Buckley P, (1998) Novel antipsychotics and the neuroleptic malignant syndrome; a review and critique. Am J Psychiatry 155: 1113 - 1116.
13. Heinemann F, Assion HJ, Hermes G, Ehrlich M, (1997) Paroxetine-induced neuroleptic malignant syndrome (Article in German). Nervenarzt 68: 664 - 666.
14. Heyland D, Sauve M, (1991) Neuroleptic malignant syndrome without the use of Neuroleptics. CMAJ 145: 817 - 819.
15. Kapur S, Langlois X, Vinken P, Megens AA, DeCoster R, Andrews JS, (2002) The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 302: 1129 - 1134.
16. Leucht S, (2004) Amisulpride a selective dopamine antagonist and atypical antipsychotic:results of a meta analysis of randomised controlled trials. Int J Neuropsychopharmacol 7 (Suppl. 1). S15 - S20.
17. Mendez MF, Lipton A, (2001) Emergent neuroleptic hypersensitivity as a herald of presenile dementia. J Neuropsychiatry Clin Neurosci 13: 347 - 356.
18. Osman AA, Khurasani MH, (1994) Lethal catatonia and neuroleptic malignant syndrome. A dopamine receptor shut down hypothesis. Br J Psychiatry 165: 548 - 550.
19. Primavera A, Fonti A, Novello P, Roccatagliata G, Cocito L, (1994) Epileptic seizures in patients with acute catatonic syndrome. J Neurol Neurosurg Psychiatry 57: 1419 - 1422.
20. Stahl SM, (2000) Essential Psychopharmacology, Neuroscientific Basis and Practical Applications, second ed. Cambridge, UK: Cambridge University Press.
21. Starr MS, (1996) The role of dopamine in epilepsy. Synapse 22: 159 - 194.
22. Supe S, Matijevic V, Kondic L, Alvir D, (2006) Series of seizures as a sign of development of recurrent malignant neuroleptic syndrome-a case report. Psychiatr Danub 18: 97 - 101.
23. Trollor JN, Sachdev PS, (1999) Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 33: 650 - 659.
24. Trollor J, Sachdev P, (2000) In reply to Dr. Lee ?catatonia and non-catatonic NMS?. Aust N Z J Psychiatry 34: 877 - 878.